Vertex Pharmaceuticals holds a dominant position in cystic fibrosis treatment, generating steady, predictable revenue that supports its premium valuation. The company is using cash flow from its cystic fibrosis franchise to invest in new areas such as pain management, hematology, and kidney diseases, with promising developments like Pove for IgA nephropathy. Non-cystic fibrosis products like Journavx and Casgevy are already contributing to revenue growth, and the renal franchise is expected to become a significant growth driver after 2027. The company's strong pipeline, solid financial health, and market position underpin a Buy rating with expectations of long-term outperformance.
